Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
India recently reported over 330,000 new COVID cases in a single day, a new world record.
There is a way to dramatically reduce these numbers.
The problem is that India, like most countries, has been following the advice recommended by the recognized authorities (NIH, CDC, WHO, and EMA) for how to prevent and treat COVID. This advice is based on evidence-based medicine (EBM) which takes a relatively long time to discover and rigorously validate effective treatments, especially for generic low-cost repurposed drugs that are off-patent.
For example, for ivermectin, in the past year, there have been 52 studies of ivermectin, 48 of them published in peer reviewed journals, and only one study was negative. However, evidence-based medicine is unable to make a conclusion one-way or the other as to whether the drug might work. A 51/52 success rate is considered “too close to call” since there could be a bias or confounder affecting all these independent studies. The fact that nobody has been able to postulate any such confounder or bias that could explain t...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).